Plasma MicroRNAs As Biomarkers In Auxiliary Diagnosis Of Cervical Carncer

Background: Cervical cancer has been one of the most common malignant tumor diseases in females. The incidence of cervical cancer tends to be younger in the world. However, there is no non-invasive blood predictive biomarker for clinical auxiliaries screening for cervical cancer currently. The micro RNAs that come from the peripheral blood plasma are often regarded to be one of the noninvasive biomarkers. The present study found that plasma micro RNA has been used in the diagnosis of many malignant tumor diseases as well as in the evaluating the disease's prognosis. These indicate that the plasma micro RNAs as a marker of malignant tumors is feasible. It is also required that non-invasive biomarkers should be used in clinical diagnosis or screening for cervical cancer. We doubt that whether there existed micro RNAs markers in cervical cancer plasma, whether the plasma micro RNA can serve as a noninvasive biomarker, potentially help screening early cervical cancer lesions.Method: Three steps were adopted in our study. We recruited 261 participants, 58 cervical cancer, 52 CINII and CINIII. Discovering phases, using a Taq Man low density arrays(TLDA) to initially screen the differential profiles of circulating micro RNA in plasma samples from 8 cervical carcinoma as cases group and 8 healthy as control group. Training phase, 50 pairs of case-control(cervical cancer, CINII and CINIII as case group; healthy as control group) matched plasma samples were applied to evaluate micro RNA concentration by real-time quantitative reverse transcriptase polymerase chain reaction(q RT-PCR) assays. Validationphrases, selected micro RNAs were further validated in 52 case group vs.93 control group(cervical cancer, CINII and CINIII as case group; healthy as control group). The study uses student's t test to evaluate statistically. The area under the curve(ROC) was used to assess diagnosis of cervical cancer and cervical precancerous lesions in specificity and sensitivity.Results: 1. This study recruited a total standard study group of 261 participants, including CINII and CINIII 52, cervical cancer 58, healthy persons151. 2. The age distributions between the case group and the control group has no significant difference(p?0.05). 3. The study found that hsa-mir-e levels in plasma of cercical cancer, CINII and CINIII was significantly expressed higher than those of healthy persons, p <0.05 and fold-change(FC)> 2.0. 4. hsa-mir-e has auxiliary diagnostic significance(AUC> 0.7 and p <0.05) between cervical cancer and healthy, has a certain diagnostic significance between CINII / CINIII and healthy subjects(AUC> 0.7 and p <0.05), hsa-mir-e has no diagnostic significance between cervical cancer and CINII / CINIII(AUC <0.7 and p> 0.05).Conclusion: The biomarker has-mir-e has showed the diagnostic value in cervical cancer as well as CINII/CINIII, plasma micro RNAs has-mir-e can be used as an effective, simple and non--invasive predictive biomarkers, but its role in the development of cervical cancer mechanism needs further study...